Biocon Biologics features on ASIA IP ELITE List 2022
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
She joins Enveda from Gilead Sciences
Advancing to IND-enabling studies with multiple drug candidates
Subscribe To Our Newsletter & Stay Updated